|
Main
|
|
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register. |
|
Register:
|
ChiCTR |
|
Last refreshed on:
|
14 May 2018 |
|
Main ID: |
ChiCTR1800016112 |
|
Date of registration:
|
2018-05-12 |
|
Prospective Registration:
|
Yes |
|
Primary sponsor: |
|
|
Public title:
|
Efficacy of Nalbuphine as adjuvant to Ropivacaine in Ultrasound guided Supraclavicular Brachial Plexus Block – A prospective randomized control trial
|
|
Scientific title:
|
Efficacy of Nalbuphine as adjuvant to Ropivacaine in Ultrasound guided Supraclavicular Brachial Plexus Block – A prospective randomized control trial |
|
Date of first enrolment:
|
2018-05-14 |
|
Target sample size:
|
Group 1:30;Group 2:30;Group 3:30; |
|
Recruitment status: |
Recruiting |
|
URL:
|
http://www.chictr.org.cn/showproj.aspx?proj=25689 |
|
Study type:
|
Interventional study |
|
Study design:
|
Randomized parallel controlled trial
|
|
Phase:
|
Other
|
|
|
Countries of recruitment
|
|
China
| | | | | | | |
|
Contacts
|
|
Name:
|
Ran Ran
|
|
Address:
|
39 Chaoyang Road, Shiyan, Hubei, China
442000
|
|
Telephone:
|
+86 18671910918 |
|
Email:
|
rmyymzjx@163.com |
|
Affiliation:
|
Shiyan People's Hospital |
|
|
Name:
|
Prakash Kalika
|
|
Address:
|
39 Chaoyang Road, Shiyan, Hubei, China
442000
|
|
Telephone:
|
+86 18772935101 |
|
Email:
|
dr.prakash_light@yahoo.com |
|
Affiliation:
|
Shiyan People's Hospital |
| |
|
Key inclusion & exclusion criteria
|
Inclusion criteria: The American Society of Anesthesiologists (ASA) physical status I and II; aged between 20 to 60 years male and female;
Patients undergoing elective orthopedic surgeries of arm, forearm and hand under supraclavicular brachial plexus block.
Exclusion criteria: 1. Patient refusal;
2. any known hypersensitivity or contraindication to ropivacaine, nalbuphine hydrochloride;
3. pregnancy, lactating mothers;
4. hepatic, renal or cardiopulmonary abnormality;
5. alcoholism;
6. diabetes;
7. long-term analgesic therapy, bleeding diathesis, and local skin site infections;
8. Patients having a history of significant neurological, psychiatric, or neuromuscular disorders.
Age minimum:
20
Age maximum:
60
Gender:
Both
|
|
Health Condition(s) or Problem(s) studied
|
|
clinical anesthesia
|
|
Intervention(s)
|
|
Group 1:ropivacaine;Group 2:ropivacaine+nalbuphine 10mg;Group 3:ropivacaine+nalbuphine 20mg;
|
|
Primary Outcome(s)
|
|
Duration of sensory block;Duration of motor block;Onset of sensory block;onset of motor block;
|
|
Secondary Outcome(s)
|
|
Duration of analgesia;Adverse events;
|
|
Source(s) of Monetary Support
|
|
postgraudate research funding of hubei medical colledge
|
|
Ethics review
|
Status: Approved
Approval date: 01/01/2018
Contact:
Shiwu wang
|
|
Results
|
|
Results available:
|
|
|
Date Posted:
|
|
|
Date Completed:
|
|
|
URL:
|
|
|
|